{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T16:32:28Z","timestamp":1775233948277,"version":"3.50.1"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.semcancer.2019.09.010","type":"journal-article","created":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T11:34:45Z","timestamp":1568979285000},"page":"3-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["What patents tell us about drug repurposing for cancer: A landscape analysis"],"prefix":"10.1016","volume":"68","author":[{"given":"Hermann A.M.","family":"Mucke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2019.09.010_bib0005","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1089\/adt.2015.29009.hmedrrr","article-title":"Sources and targets for drug repurposing: landscaping transitions in therapeutic space","volume":"13","author":"Mucke","year":"2015","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.semcancer.2019.09.010_bib0010","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.celrep.2016.12.051","article-title":"Chloroquine-inducible par-4 secretion is essential for tumor cell apoptosis and inhibition of metastasis","volume":"18","author":"Burikhanov","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.semcancer.2019.09.010_bib0015","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/ni.3201","article-title":"Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy","volume":"16","author":"Barreira da Silva","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.semcancer.2019.09.010_bib0020","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/0971-5916.180201","article-title":"Targeting the AKT pathway: repositioning HIV protease inhibitors as radiosensitizers","volume":"143","author":"Goda","year":"2016","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.semcancer.2019.09.010_bib0025","doi-asserted-by":"crossref","first-page":"e1013","DOI":"10.1097\/MD.0000000000001013","article-title":"Combination therapy of metformin and statin may decrease hepatocellular carcinoma among diabetic patients in Asia","volume":"94","author":"Chen","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.semcancer.2019.09.010_bib0030","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1016\/j.vaccine.2018.04.020","article-title":"Back to the future \u2013 is the drug repositioning concept applicable to vaccines?","volume":"36","author":"Schwamborn","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.semcancer.2019.09.010_bib0035","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2407-13-4","article-title":"Human endogenous retroviruses and cancer prevention: evidence and prospects","volume":"13","author":"Cegolon","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.semcancer.2019.09.010_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006451","article-title":"A human endogenous retrovirus-derived gene that can contribute to oncogenesis by activating the ERK pathway and inducing migration and invasion","volume":"13","author":"Lema\u00eetre","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.semcancer.2019.09.010_bib0045","doi-asserted-by":"crossref","first-page":"84093","DOI":"10.18632\/oncotarget.11455","article-title":"Activation of HERV-K Env protein is essential for tumorigenesis and metastasis of breast cancer cells","volume":"7","author":"Zhou","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2019.09.010_bib0050","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40425-018-0495-7","article-title":"Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics","volume":"7","author":"Guo","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.semcancer.2019.09.010_bib0055","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/CEJ.0000000000000333","article-title":"Yellow fever vaccine 17D administered to healthy women aged between 40 and 54 years halves breast cancer risk: an observational study","volume":"27","author":"Mastrangelo","year":"2018","journal-title":"Eur. J. Cancer Prev."}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X19302810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X19302810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:48:12Z","timestamp":1760917692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X19302810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":11,"alternative-id":["S1044579X19302810"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2019.09.010","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What patents tell us about drug repurposing for cancer: A landscape analysis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2019.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}